Valneva (NASDAQ:VALN) Sees Large Volume Increase – Here’s Why

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN) saw unusually-strong trading volume on Friday . Approximately 33,435 shares traded hands during mid-day trading, an increase of 140% from the previous session’s volume of 13,941 shares.The stock last traded at $9.6050 and had previously closed at $9.33.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen cut Valneva from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Valneva has an average rating of “Moderate Buy” and an average price target of $15.00.

Valneva Trading Up 1.2%

The firm has a market capitalization of $813.28 million, a price-to-earnings ratio of -6.56 and a beta of 1.84. The company has a quick ratio of 1.36, a current ratio of 1.78 and a debt-to-equity ratio of 0.72. The firm’s 50 day moving average is $9.14 and its 200 day moving average is $9.30.

Valneva (NASDAQ:VALN) last posted its quarterly earnings results on Thursday, November 20th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.31). The business had revenue of $34.01 million during the quarter, compared to analyst estimates of $48.85 million. Valneva had a negative return on equity of 59.44% and a negative net margin of 57.81%. Equities analysts forecast that Valneva SE Sponsored ADR will post 0.13 earnings per share for the current year.

Institutional Trading of Valneva

Several institutional investors and hedge funds have recently bought and sold shares of VALN. China Universal Asset Management Co. Ltd. acquired a new position in shares of Valneva in the fourth quarter worth about $44,000. JPMorgan Chase & Co. purchased a new stake in shares of Valneva in the 3rd quarter valued at approximately $124,000. VSM Wealth Advisory LLC boosted its stake in Valneva by 125.0% in the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock worth $110,000 after purchasing an additional 5,000 shares during the period. Marex Group plc purchased a new position in Valneva during the 2nd quarter worth approximately $64,000. Finally, Frazier Life Sciences Management L.P. acquired a new stake in Valneva during the 2nd quarter valued at $8,240,000. Institutional investors and hedge funds own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.